Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

BACKGROUND: The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab. We report findings in high-risk patients (FL Internationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, Pier Luigi, Khuageva, Nuriet K, Wang, Huaqing, Garicochea, Bernardo, Walewski, Jan, Van Hoof, Achiel, Soubeyran, Pierre, Caballero, Dolores, Buckstein, Rena, Esseltine, Dixie-Lee, Theocharous, Panteli, Enny, Christopher, Zhu, Eugene, Elsayed, Yusri A, Coiffier, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502148/
https://www.ncbi.nlm.nih.gov/pubmed/23088650
http://dx.doi.org/10.1186/1756-8722-5-67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502148/
https://www.ncbi.nlm.nih.gov/pubmed/23088650
http://dx.doi.org/10.1186/1756-8722-5-67

Ejemplares similares